Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors

Despite state of the art cancer diagnostics and therapies offered in clinic, prostate cancer (PCa) remains the second leading cause of cancer-related deaths. Hence, more robust therapeutic/preventive regimes are required to combat this lethal disease. In the current study, we have tested the efficac...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Cycle
Auteurs principaux: Mir, Hina, Kapur, Neeraj, Singh, Rajesh, Sonpavde, Guru, Lillard, James W., Singh, Shailesh
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2016
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845948/
https://ncbi.nlm.nih.gov/pubmed/27029529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2016.1148836
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires